Drugs / AVANZ Phleum pratense
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01454531 | Jun 2011 → Mar 2012 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02166268 Comparator | Jun 2014 → Oct 2015 | seasonal allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 2/3 | NCT01438827 Comparator | Sep 2011 → Dec 2012 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVANZ Phleum pratense | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01454531 ↗ |
| Known as | Avanz SQ+ | “The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass...” NCT01438827 ↗ |
| Route | Subcutaneous | “suspension for subcutaneous injection” NCT02166268 ↗ |